Hemophilia is treated by replacing or compensating for the missing clotting factor in the blood. For most people with severe hemophilia, this means regular infusions of clotting factor concentrates to prevent bleeding episodes before they start. The specific treatment depends on the type of hemophilia (A or B), its severity, and whether the body has developed resistance to standard therapy.
Preventive Factor Replacement
The backbone of hemophilia treatment is prophylaxis: scheduled infusions of the clotting factor the body can’t produce on its own. People with hemophilia A receive factor VIII concentrates, while those with hemophilia B receive factor IX. The goal is to keep enough clotting factor circulating in the blood to prevent spontaneous bleeds, especially into joints and muscles.
Standard factor VIII concentrates have a half-life of about 12 hours, meaning half the infused factor is gone within that time. Factor IX lasts a bit longer at 18 to 24 hours. Because of this relatively quick clearance, people on standard products typically infuse every other day or three times per week for hemophilia A, and twice weekly for hemophilia B. Each infusion is given intravenously, and many people learn to do this at home.
Extended half-life products have changed the routine for many patients. These engineered concentrates last 1.5 to 2 times longer for factor VIII (reaching about 19 hours) and 4 to 6 times longer for factor IX (reaching 82 to 102 hours). The practical difference is significant: people with hemophilia A on extended half-life products can infuse twice a week or every four days instead of every other day, while those with hemophilia B may only need an infusion once a week or even once every two weeks.
Treatment for Mild Hemophilia
Not everyone with hemophilia needs regular factor infusions. Hemophilia severity is based on how much clotting factor the body produces naturally. People with mild hemophilia A have factor VIII levels between 6 and 40 percent of normal, and they typically bleed only after injuries or surgical procedures rather than spontaneously.
For these patients, a synthetic hormone called desmopressin (DDAVP) is often enough to handle minor bleeds and small procedures. It works by stimulating the body to release its own stored factor VIII into the bloodstream, temporarily boosting levels high enough to control bleeding. Desmopressin can also be effective in about 40% of cases for people with moderate hemophilia (factor levels between 1 and 5 percent) when the bleeding event is minor. It’s given as an injection or nasal spray and avoids the need for clotting factor concentrates entirely in many situations. For major surgeries or more serious bleeds, factor concentrates are still necessary.
Emicizumab: A Non-Factor Alternative
Emicizumab represents a fundamentally different approach to hemophilia A treatment. Rather than replacing the missing factor VIII, this lab-engineered antibody mimics what factor VIII does. It bridges two other clotting proteins (activated factor IX and factor X) in the same way factor VIII normally would, restoring the clotting chain.
The advantages over traditional factor replacement are practical and substantial. Emicizumab is injected under the skin rather than into a vein, which is simpler and faster. It has a half-life of about 30 days, so it can be given once a week, every two weeks, or even once a month. For children and adults who find frequent intravenous infusions burdensome, this is a major quality-of-life improvement. Treatment begins with a four-week loading phase of weekly injections, then transitions to the chosen maintenance schedule.
Emicizumab works for hemophilia A regardless of whether the patient has developed inhibitors (antibodies that neutralize infused factor VIII), which makes it especially valuable for a group that previously had limited options.
When the Body Rejects Factor Replacement
One of the most serious complications in hemophilia treatment is the development of inhibitors. These are antibodies the immune system produces against infused clotting factor, essentially attacking the treatment and making it ineffective. Inhibitors occur more commonly in hemophilia A than hemophilia B.
When inhibitors develop, standard factor replacement no longer works at normal doses. Instead, treatment shifts to “bypassing agents” that activate the clotting cascade through an alternate route, working downstream from the point where the inhibitor blocks the process. Two products fill this role. One is a plasma-derived activated prothrombin complex concentrate that works by converting prothrombin into thrombin, the enzyme that ultimately forms a clot. The other is a recombinant activated factor VII product that enhances clot formation directly on the surface of activated platelets, producing a tighter, more stable clot.
Both bypassing agents are used to treat active bleeds, to cover surgical procedures, and in some cases for ongoing prophylaxis. Emicizumab has become a preferred preventive option for many hemophilia A patients with inhibitors, since it works through a completely different mechanism that inhibitors don’t affect.
Gene Therapy
Gene therapy aims to provide a longer-lasting solution by delivering a working copy of the defective gene so the body can manufacture its own clotting factor. Two gene therapies have received FDA approval: one for hemophilia B and one for hemophilia A. Both use a harmless virus (adeno-associated virus) to carry the corrected gene into liver cells, where clotting factors are naturally produced.
For hemophilia A, the approved gene therapy (valoctocogene roxaparvovec) produced median factor VIII activity levels of about 40 percent of normal at one year after a single intravenous infusion. That’s well within the mild hemophilia range and high enough to prevent most spontaneous bleeds. However, factor levels decline over time. By year two, the median dropped to about 23 percent, and by year three it was around 17 percent. Data out to six years shows continued decline without a clear plateau, which means some patients may eventually need to resume other treatments.
The hemophilia B gene therapy has shown more stable, sustained factor IX production over multiple years. This likely reflects biological differences in how the two clotting factors are produced and maintained by liver cells.
Gene therapy is currently a one-time treatment, given as a single infusion. It requires a period of liver monitoring afterward, and patients need to avoid alcohol and certain medications that stress the liver during the initial months. Not everyone is a candidate: people with pre-existing antibodies to the viral delivery vehicle, significant liver disease, or active inhibitors are generally excluded.
Newer Approaches on the Horizon
Several therapies in development take yet another strategy: instead of replacing the missing clotting factor or mimicking it, they dial down the body’s natural anticoagulant systems to rebalance the clotting equation. One approach uses a small interfering RNA molecule to suppress production of antithrombin, a natural blood-thinning protein. By lowering antithrombin levels, the blood’s ability to clot is partially restored even without normal clotting factor levels. This approach works for both hemophilia A and hemophilia B, which is notable since emicizumab only covers hemophilia A.
Another group of therapies targets tissue factor pathway inhibitor (TFPI), a protein that normally puts the brakes on early clotting reactions. Several antibody-based drugs are being tested that block TFPI at different points, freeing up the clotting cascade to proceed more effectively. Like the antithrombin-targeting approach, these are given as subcutaneous injections and could benefit patients with either type of hemophilia.
These “rebalancing” therapies are attractive because they sidestep the inhibitor problem entirely and could offer simple dosing schedules for a broader range of patients. Clinical trials are ongoing to establish their long-term safety and effectiveness.